REGN 2810

Drug Profile

REGN 2810

Alternative Names: PD-1 protein inhibitor - Regeneron; REGN2810; SAR 439684

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Squamous cell cancer
  • Phase I B cell lymphoma; Cancer; Lymphoma
  • Phase Unknown Malignant melanoma

Most Recent Events

  • 20 Dec 2016 Investigation in Malignant melanoma in United Kingdom (Parenteral) before December 2016
  • 20 Dec 2016 Regeneron Pharmaceuticals and Sanofi plan an exploratory phase I trial for Malignant melanoma (First-line therapy, Late-stage disease, Inoperable/Unresectable) in United Kingdom (Parenteral) (NCT03002376)
  • 01 Nov 2016 Phase-I clinical trials in Cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Parenteral) (NCT03005782)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top